A61K 51/1078
The antibody being against an immunoglobulin, i.e. being an -anti-idiotypic antibody
Official title: {the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody}
A61K51/1078 (The antibody being against an immunoglobulin, i.e. being an -anti-idiotypic antibody) appears on 20 US grants and 25 published applications in this corpus.
Search patents in A61K- Granted patents
- 20
- Published applications
- 25
- Assignees
- 18
- Inventors
- 63
- Latest grant
- 30 May 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 3 |
| 2011 | 0 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 2 |
| 2015 | 1 | 1 |
| 2016 | 0 | 2 |
| 2017 | 1 | 2 |
| 2018 | 2 | 3 |
| 2019 | 0 | 0 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 2 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response30 May 2023US 11,660,356 B2Vrije Universiteit Brussel
- Antibodies that bind activatable antibodies and methods of use thereof25 Feb 2020US 10,568,977 B2CytomX Therapeutics, Inc.
- Uses of monoclonal antibody 8H910 Apr 2018US 9,938,351 B2Sloan-Kettering Institute for Cancer Research
- Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer2 Jan 2018US 9,855,348 B2Vrije Universiteit Brussel
- Antibodies that bind activatable antibodies and methods of use thereof22 Aug 2017US 9,737,623 B2CytomX Therapeutics, Inc.
- Method for producing complex5 Jun 2025US 2025/0177583 A1Nihon Medi-Physics Co., Ltd.
- Igg epitope and applications thereof as a drug target12 Dec 2024US 2024/0409616 A1Guangzhou Sig Biopharmaceutical Technology Co., Ltd.
- Methods of treating neoplastic astrocytoma11 Apr 2024US 2024/0117073 A1Ludwig Institute for Cancer Research
- Methods of treating neoplastic astrocytoma4 Feb 2021US 2021/0032366 A1Ludwig Institute for Cancer Research
- Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response3 Sep 2020US 2020/0276340 A1Vrije Universiteit Brussel
Most cited
By later US patents
- Antibodies to human carcinoma antigen83US 5,693,763 AEpigen, Inc. · 1997
- Human carcinoma antigen35US 5,808,005 AEpigen, Inc. · 1998
- Treatment and delay of outset of Parkinson's disease30US 7,727,957 B2Janssen Alzheimer Immunotherapy · 2010
- Delivery of diagnostic and therapeutic agents to a target site23US 5,958,408 AImmunomedics, Inc. · 1999
- Antibodies that bind activatable antibodies and methods of use thereof23US 9,737,623 B2CytomX Therapeutics, Inc. · 2017